This suggests a possible upside of 3.3% from the stock's current price. BeiGene Those metrics have NOTHING to do with what makes stocks rise or fall.
As of February 27, 2019, the Company had a global team of over 2,200 employees. The company's average rating score is 2.62, and is based on 8 buy ratings, 5 hold ratings, and no sell ratings.According to analysts' consensus price target of $216.30, Beigene has a potential upside of 3.3% from its current price of $209.45.Beigene has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Beigene has received 55.54% “outperform” votes from our community.Beigene does not have a long track record of dividend growth.In the past three months, Beigene insiders have sold more of their company's stock than they have bought.
High institutional ownership can be a signal of strong market trust in this company.Earnings for Beigene are expected to grow in the coming year, from ($19.86) to ($18.37) per share.The P/E ratio of Beigene is -10.21, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.The P/E ratio of Beigene is -10.21, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Beigene has a P/B Ratio of 13.20. As of February 27, 2019, the Company had a global team of over 2,200 employees. It focuses on Zanubrutinib (BGB-3111), Tislelizumab (BGB-A317), and Pamiparib (BGB-290). On average, they expect Beigene's stock price to reach $215.75 in the next year.
Specifically, they have bought $0.00 in company stock and sold $45,099,316.00 in company stock.Only 11.00% of the stock of Beigene is held by insiders.63.78% of the stock of Beigene is held by institutions. Registration on or use of this site constitutes acceptance of our Beigene Ltd (NASDAQ:BGNE) released its quarterly earnings data on Thursday, August, 6th. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist.
Please log in to your account or sign up in order to add this asset to your watchlist. Cancer has no borders. The company's clinical stage drug candidates include BGB-3111, a small molecule Bruton's tyrosine kinase (BTK) inhibitor for the treatment of lymphomas; BGB-A317, a humanized monoclonal antibody for solid and hematological cancers; and BGB-290, a small molecule inhibitor of PARP1 and PARP2 for the treatment of homologous recombination deficient cancers. BeiGene Stock Key Figures MORE Market Cap (USD) BGNE stock was sold by a variety of institutional investors in the last quarter, including Russell Investments Group Ltd., Matthews International Capital Management LLC, DekaBank Deutsche Girozentrale, Macquarie Group Ltd., Sumitomo Mitsui Trust Holdings Inc., Vident Investment Advisory LLC, Vident Investment Advisory LLC, and Mckinley Capital Management LLC Delaware. BeiGene was established in Beijing in 2010 and listed on the U.S. NASDAQ Global Select Market in February 2016. View our full suite of financial calendars and market data tables, all for free.Receive a free world-class investing education from MarketBeat.
"Beigene's stock is owned by a variety of institutional and retail investors. The company has collaborations with Celgene Corporation, Merck KGaA, Mirati Therapeutics, Inc., Zymeworks, BioAtla, LLC, and Ambrx, Inc. BeiGene, Ltd. was founded in 2010 and is based in George Town, the Cayman Islands.This is how wealth is really made in the stock market today.Beigene's management team includes the following people: Co-Founder, Chairman of the Scientific Advisory Board & Director BGNE stock was bought by a variety of institutional investors in the last quarter, including MERIAN GLOBAL INVESTORS UK Ltd, Candriam Luxembourg S.C.A., M&G Investment Management Ltd., Edmond DE Rothschild Holding S.A., New York State Common Retirement Fund, Swiss National Bank, Banco de Sabadell S.A, and Jennison Associates LLC.
Shares of BGNE can be purchased through any online brokerage account.
The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. EUR Beigene is scheduled to release its next quarterly earnings announcement on Tuesday, November 10th 2020. 13 equities research analysts have issued 1 year price targets for Beigene's stock. Beigene earned a daily sentiment score of -2.6 on InfoTrie's scale.
Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.
13 Wall Street analysts have issued 12 month price objectives for Beigene's shares.
On average, they anticipate Beigene's share price to reach $216.30 in the next year.
BeiGene at EHA25 Visit BeiGene’s virtual booth at the 25th Virtual EHA Congress Contact Us Connect with our team in Europe and across the globe European Leadership An overview of our presence in Europe . Want to see which stocks are moving?